Catalyst Pharmaceuticals Inc (CPRX)vsBeiGene, Ltd. (ONC)
CPRX
Catalyst Pharmaceuticals Inc
$31.15
-0.05%
HEALTHCARE · Cap: $3.81B
ONC
BeiGene, Ltd.
$317.00
+1.17%
HEALTHCARE · Cap: $33.06B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 807% more annual revenue ($5.34B vs $588.99M). CPRX leads profitability with a 36.4% profit margin vs 5.4%. CPRX trades at a lower P/E of 18.6x. CPRX earns a higher WallStSmart Score of 57/100 (C).
CPRX
Buy57
out of 100
Grade: C
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CPRX.
Margin of Safety
+79.5%
Fair Value
$1717.18
Current Price
$317.00
$1400.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 40.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Earnings declined 6.4%
Trading at 8.1x book value
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : CPRX
The strongest argument for CPRX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 36.4% and operating margin at 40.5%.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CPRX
The primary concerns for CPRX are Piotroski F-Score, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are Price/Book, EPS Growth, Return on Equity. A P/E of 120.4x leaves little room for execution misses.
Key Dynamics to Monitor
CPRX profiles as a mature stock while ONC is a hypergrowth play — different risk/reward profiles.
CPRX carries more volatility with a beta of 0.72 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
CPRX scores higher overall (57/100 vs 42/100), backed by strong 36.4% margins. ONC offers better value entry with a 79.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Catalyst Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?